Search results
Results from the WOW.Com Content Network
The strong association with fatigue after COVID-19 reinforces the need for public health actions to prevent SARS-CoV-2 infections, to provide clinical care, and to find effective treatment for ...
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
People with the COVID-19 infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: a respiratory symptom cluster with cough, sputum , shortness of breath , and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; and a cluster of ...
The CDC describes long COVID as a wide range of ongoing symptoms and conditions that can last weeks, months or even years after COVID-19 illness. Anyone who has had the SARS-CoV-2 infection − ...
With a severe case of COVID-19, a person may experience weakness, lethargy, and fever for a prolonged period of time. However, in some cases, a person might not even show symptoms of having the ...
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [57] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [22]
The symptoms of HV.1 and other COVID-19 variants can look very similar to other viruses, including respiratory syncytial virus (RSV), influenza and rhinovirus, which usually causes the common cold.
Nirmatrelvir/ritonavir has been evaluated in the treatment of COVID‑19 in standard-risk individuals in the EPIC-SR trial. [51] [53] This study did not achieve its primary goal of reducing time to sustained alleviation of COVID‑19 symptoms (treatment: 13 days (95% CI 12–15 days); placebo: 13 days (95% CI 11–14 days)).